BridgeMD
New treatment option for High Myopia
Official title The Role of Capsular Tension Rings in Intraocular Lens Stability in High Myopia Cataract Patients: A Prospective Self-Controlled Study
ClinicalTrials.gov ID: NCT07052825
What this study is testing
- What it's testing
- Study Purpose: This prospective, self-controlled clinical study aims to evaluate the impact of capsular tension rings (CTR) on intraocular lens (IOL) stability in high myopia patients undergoing bilateral cataract surgery. Each patient will receive CTR implantation in one eye, with the fellow eye serving as control.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- Age ≥ 18 years.
- Diagnosed with bilateral age-related cataracts and scheduled for phacoemulsification with IOL implantation in both eyes.
- High myopia in both eyes, defined as axial length (AL) ≥ 26.0 mm.
- No significant difference in axial length between the two eyes (e.g., interocular AL difference \< 1.0 mm).
- Willingness and ability to undergo bilateral surgery within a short interval (e.g., within 1-2 weeks).
You likely can't join if
- History of ocular trauma, surgery, or intraocular inflammation in either eye.
- Presence of other ocular diseases that may affect visual outcomes, such as glaucoma, diabetic retinopathy, macular degeneration, or corneal opacity.
- Evidence of zonular weakness, pseudoexfoliation, or significant phacodonesis preoperatively.
- Severe dry eye or poor fixation that may interfere with postoperative imaging.
- Systemic diseases affecting visual function (e.g., uncontrolled diabetes, neurologic disorders).
- Participation in other clinical trials that may affect the study outcomes.
See the full eligibility criteria
- Age ≥ 18 years.
- Diagnosed with bilateral age-related cataracts and scheduled for phacoemulsification with IOL implantation in both eyes.
- High myopia in both eyes, defined as axial length (AL) ≥ 26.0 mm.
- No significant difference in axial length between the two eyes (e.g., interocular AL difference \< 1.0 mm).
- Willingness and ability to undergo bilateral surgery within a short interval (e.g., within 1-2 weeks).
- Able to provide informed consent and comply with the study protocol and follow-up visits.
- History of ocular trauma, surgery, or intraocular inflammation in either eye.
- Presence of other ocular diseases that may affect visual outcomes, such as glaucoma, diabetic retinopathy, macular degeneration, or corneal opacity.
- Evidence of zonular weakness, pseudoexfoliation, or significant phacodonesis preoperatively.
- Severe dry eye or poor fixation that may interfere with postoperative imaging.
- Systemic diseases affecting visual function (e.g., uncontrolled diabetes, neurologic disorders).
- Participation in other clinical trials that may affect the study outcomes.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.